Corona Remedies
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
CORONA Remedies Limited is poised for robust growth, driven by a strategic focus on key therapeutic areas such as Women’s Healthcare and Pain Management, alongside recent capacity expansions and acquisitions. Management's commitment to achieving 15% organic revenue growth and 20% PAT growth for FY27 reflects confidence in their operational strategy, despite facing short-term cost pressures from geopolitical factors and rising employee expenses. The commissioning of an EU-GMP facility enhances their competitive position, enabling both domestic leadership and international expansion. Vista's financial outlook aligns with these developments, forecasting stable revenue growth and margins, supported by a favorable industry backdrop characterized by improving pricing power and resilient demand in chronic therapies. However, potential headwinds include rising input costs and execution risks in new therapeutic areas. Over the next 12-24 months, CORONA's focus on deepening specialist engagement and leveraging new manufacturing capabilities will be critical for sustaining growth. The company is well-positioned to capitalize on market opportunities, although vigilance is required regarding external uncertainties and competitive pressures
Why We Like This Stock
- Management's focus on key therapeutic areas is expected to drive significant revenue growth
- The commissioning of an EU-GMP facility positions CORONA for both domestic leadership and international market expansion
- Recent acquisitions enhance market presence and are anticipated to contribute positively to revenue and profitability
Things To Watch Out For
- Short-term cost pressures from geopolitical volatility and rising employee-related expenses may impact margins
- Execution risks associated with entering new therapeutic areas could hinder growth potential
- Rising input costs and pricing challenges in the US market may pose threats to profitability
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,014 | 1,196 | 1,403 | 1,510 | 1,725 |
| Profit Before Tax (Cr.) | 119 | 200 | 259 | 269 | 310 |
| PBT Margin | 11.7% | 16.7% | 18.5% | 17.8% | 18.0% |
| Net Profit (Cr.) | 97 | 154 | 199 | 206 | 238 |
| Earnings Per Share | 15.8 | 25.1 | 32.6 | 33.7 | 38.9 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women's healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.